Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Gillison ML, et al. Among authors: licitra l. Oncologist. 2022 Mar 4;27(2):e194-e198. doi: 10.1093/oncolo/oyab036. Oncologist. 2022. PMID: 35641218 Free PMC article.
Biological agents in head and neck cancer.
Bossi P, Locati LD, Licitra L. Bossi P, et al. Among authors: licitra l. Expert Rev Anticancer Ther. 2007 Nov;7(11):1643-50. doi: 10.1586/14737140.7.11.1643. Expert Rev Anticancer Ther. 2007. PMID: 18020930 Review.
Human papillomavirus in HNSCC: a European epidemiologic perspective.
Licitra L, Zigon G, Gatta G, Sánchez MJ, Berrino F; EUROCARE Working Group. Licitra L, et al. Hematol Oncol Clin North Am. 2008 Dec;22(6):1143-53, vii-viii. doi: 10.1016/j.hoc.2008.10.002. Hematol Oncol Clin North Am. 2008. PMID: 19010264 Review.
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Stewart JS, et al. Among authors: licitra l. J Clin Oncol. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289630 Clinical Trial.
Targeted therapy in head and neck cancer.
Licitra L, Bergamini C, Mirabile A, Granata R. Licitra L, et al. Curr Opin Otolaryngol Head Neck Surg. 2011 Apr;19(2):132-7. doi: 10.1097/MOO.0b013e328344b668. Curr Opin Otolaryngol Head Neck Surg. 2011. PMID: 21372717 Review.
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Urba S, et al. Among authors: licitra l. Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20. Cancer. 2012. PMID: 22434360 Free article. Clinical Trial.
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Licitra L, et al. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265711 Clinical Trial.
440 results